Novonesis (Novozymes A/S) Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

8,362.04

7,443.03

7,947.87

7,599.60

8,038.78

7,320.08

7,612.83

Other Operating Income

0.00

Total Operating income

8,362.04

7,443.03

7,947.87

7,599.60

8,038.78

7,320.08

7,612.83

Raw Material Cost

3,624.07

3,270.42

3,887.73

3,536.78

3,605.36

3,621.25

3,518.43

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

64.25

125.47

111.95

117.15

143.98

135.00

141.01

Selling and Distribution Expenses

1,829.59

1,864.87

1,713.62

1,643.04

1,583.73

1,566.35

1,462.28

Other Expenses

83.90

83.27

77.32

70.06

65.65

69.14

66.40

Total Expenditure (Excl Depreciation)

6,356.88

6,093.49

6,486.52

5,997.60

5,989.54

6,014.04

5,785.72

Operating Profit (PBDIT) excl Other Income

2005.2

1349.5

1461.3999999999999

1602

2049.2

1306

1827.1000000000001

Other Income

36.61

53.77

25.38

38.05

7.46

84.28

-8.95

Operating Profit (PBDIT)

3,160.14

2,722.99

2,580.13

2,659.30

3,079.44

2,556.88

2,830.56

Interest

64.25

125.47

111.95

117.15

143.98

135.00

141.01

Exceptional Items

-48.56

-114.27

-97.77

-203.70

-76.09

-449.02

-29.10

Gross Profit (PBDT)

4,737.97

4,172.61

4,060.14

4,062.82

4,433.41

3,698.82

4,094.39

Depreciation

1,118.38

1,319.67

1,093.40

1,019.25

1,022.75

1,166.56

1,012.41

Profit Before Tax

1,928.95

1,163.58

1,277.00

1,319.20

1,836.62

806.30

1,648.05

Tax

431.81

223.31

250.03

281.30

437.90

161.11

474.50

Provisions and contingencies

0.00

Profit After Tax

1,487.43

917.12

1,029.96

1,020.74

1,387.54

642.95

1,161.62

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

1,487.43

917.12

1,029.96

1,020.74

1,387.54

642.95

1,161.62

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

1,487.43

917.12

1,029.96

1,020.74

1,387.54

642.95

1,161.62

Equity Capital

0.00

Face Value

0.0

Reserves

81,596.47

81,077.84

80,199.76

80,150.15

83,787.96

83,342.30

81,968.42

Earnings per share (EPS)

3.19

1.93

2.21

2.19

2.98

1.38

2.5

Diluted Earnings per share

3.19

1.93

2.21

2.19

2.98

1.38

2.5

Operating Profit Margin (Excl OI)

23.98%

18.13%

18.39%

21.08%

25.49%

17.84%

24.0%

Gross Profit Margin

36.44%

33.36%

29.82%

30.77%

35.57%

26.95%

34.95%

PAT Margin

17.79%

12.32%

12.96%

13.43%

17.26%

8.78%

15.26%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is 12.35% vs -6.35% in Dec 2025

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 62.19% vs -10.96% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 17.02% vs 4.48% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is -48.84% vs 12.05% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Novonesis (Novozymes A/S) With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(DKK)

Change(%)

Net Sales

8,362.04

Other Operating Income

0.00

Total Operating income

8,362.04

Raw Material Cost

3,624.07

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

64.25

Selling and Distribution Expenses

1,829.59

Other Expenses

83.90

0.00

83.90

Total Expenditure (Excl Depreciation)

6,356.88

Operating Profit (PBDIT) excl Other Income

2,005.16

0.00

2,005.16

Other Income

36.61

Operating Profit (PBDIT)

3,160.14

Interest

64.25

Exceptional Items

-48.56

Gross Profit (PBDT)

4,737.97

Depreciation

1,118.38

Profit Before Tax

1,928.95

Tax

431.81

Provisions and contingencies

0.00

Profit After Tax

1,487.43

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

1,487.43

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

1,487.43

Equity Capital

0.00

Face Value

0.00

Reserves

81,596.47

Earnings per share (EPS)

3.19

Diluted Earnings per share

3.19

Operating Profit Margin (Excl OI)

23.98%

0.00

23.98%

Gross Profit Margin

36.44%

0.00

36.44%

PAT Margin

17.79%

0.00

17.79%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 836.20 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 12.35% vs -6.35% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 4.02% vs 26.32% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 148.74 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 62.19% vs -10.96% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 7.20% vs 458.80% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 312.35 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 17.02% vs 4.48% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 1.68% vs 84.11% in Mar 2025

Quarterly - Interest

Interest 6.42 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -48.84% vs 12.05% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -55.42% vs 2.20% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 23.98%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025